Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01837329 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer
A Phase 1 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01837329 is a Phase 1 study that has completed, run by University of Rochester. The registered enrollment target is 26 participants.
The verdict
NCT01837329, a Phase 1 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The main objective of this study is to determine recommended phase II dose and safety of tetrathiomolybdate (TM) in combination with carboplatin and pemetrexed in chemo-naive metastatic or recurrent non-squamous non-small cell lung cancer.
Interventions
- DRUG Tetrathiomolybdate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2013-11 |
| Est. Completion | 2019-01-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01837329
The ClinicalTrials.gov registry entry for NCT01837329 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tetrathiomolybdate is the first listed.
NCT01837329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01837329 about?
NCT01837329 is a clinical study titled "Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer". The main objective of this study is to determine recommended phase II dose and safety of tetrathiomolybdate (TM) in combination with carboplatin and pemetrexed in chemo-naive metastatic or recurrent non-squamous non-small cell lung cancer.
What is the current status of trial NCT01837329?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2013-11. Estimated completion is 2019-01-11.
What interventions are being tested in trial NCT01837329?
The interventions under investigation include: Tetrathiomolybdate (DRUG).
Who is sponsoring clinical trial NCT01837329?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.